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Targeted therapy is a promising approach for treatment of neuroblastoma as evident
from the large number of targeting agents employed in clinical practice today. In
the absence of known crystal structures, researchers rely on homology modeling to
construct template-based theoretical structures for drug design and testing. Here,
we discuss three candidate cell surface proteins that are suitable for homology
modeling: human norepinephrine transporter (hNET), anaplastic lymphoma kinase
(ALK), and neurotrophic tyrosine kinase receptor 2 (NTRK2 or TrkB). When choosing
templates, both sequence identity and structure quality are important for homology
modeling and pose the first of many challenges in the modeling process. Homology
modeling of hNET can be improved using template models of dopamine and
serotonin transporters instead of the leucine transporter (LeuT). The extracellular
domains of ALK and TrkB are yet to be exploited by homology modeling. There
are several idiosyncrasies that require direct attention throughout the process of
model construction, evaluation and refinement. Shifts/gaps in the alignment between
the template and target, backbone outliers and side-chain rotamer outliers are
among the main sources of physical errors in the structures. Low-conserved regions
can be refined with loop modeling method. Residue hydrophobicity, accessibility
to bound metals or glycosylation can aid in model refinement. We recommend
resolving these idiosyncrasies as part of “good modeling practice” to obtain highest
quality model. Decreasing physical errors in protein structures plays major role in the
development of targeting agents and understanding of chemical interactions at the
molecular level.
Keywords: neuroblastoma, targeted therapy, homology modeling, norepinephrine transporter, anaplastic
lymphoma kinase, neurotrophic tyrosine kinase receptor
INTRODUCTION
The large number of experimentally determined and deposited protein structures in the databases
is a valuable source to explore uncharted territories of other proteins, which have similar sequence.
Homology modeling, also known as comparative modeling, is used for constructing protein models
based on template structures of homolog proteins. In this perspective article, we have highlighted
the main structural issues in homology modeling of three candidate cell surface proteins for
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neuroblastoma targeted therapy. In the next section, we
emphasize the challenges faced in each step in the homology
modeling process. A brief section on targeting neuroblastoma
describes the role of cell surface protein targets in developing
therapeutics. A detailed evaluation of homology models
expands on three chosen cell surface protein candidates: human
norepinephrine transporter (hNET), anaplastic lymphoma
kinase (ALK), and neurotrophic tyrosine kinase receptor type 2
(NTRK2, commonly known as TrkB). While the technical
aspects of this manuscript favor an audience of specialists
working on drug discovery and homology modeling of these
three targets, the same principles of model evaluation and
challenging issues can be applied for other homology models.
HOMOLOGY MODELING
Protein structures are the final frontiers in understanding
the human biology at the molecular level. Gold standards of
crystal structure characterization at atomic resolution, such as
X-ray crystallography and nuclear magnetic resonance (NMR)
spectroscopy, can be now satisfactorily complemented with
computational methods (Kundrotas et al., 2012). Homology
modeling is a systematic computational process where the
most similar protein sequence, of a known crystal structure,
is used for construction of a new model by replacing the
equivalent amino acids on an equivalent backbone. Krieger
et al. (2003) described seven steps in homology modeling:
(1) The choice of template(s) and initial alignment are the first
challenges in homology modeling. The accuracy of a homology
model is correlated with the number of matching residues in
alignment. A minimum 25% sequence identity has been the
standard for homology modeling so far. Below 25% identity it
is recommended to use multiple templates for modeling. The
quality of template structure is directly inherited in the homology
model. Polishing of template structure is a good practice before
use. Missing atoms should be fixed using rotamer library and
the hanging termini can be trimmed. (2) Alignment correction
reduces errors caused by false sequence identities. Multiple
alignments and structural alignments (e.g., position-specific
scoring matrices) are recommended alternatives to conventional
alignments. This step is the most critical in homology modeling
before (3) backbone generation, as it determines the torsional
angles of the backbone in the model. It has been shown that
problems in the backbone can drastically alter the correct
folding of the side-chains as well (Al-Lazikani et al., 2001).
Issues regarding template recognition and alignment will be
highlighted here. From our experience, many of the sporadic
errors in modeling backbones arise in proline or adjacent to
proline residues. (4) Loop modeling is important for correcting
the folding of low-conserved regions (i.e., loops) of protein.
It is now possible to make accurate models using database
search or ab initio methods for up to 8–13 residues long loops
(Totrov, 2012). Loop modeling employs potential energy scores
for evaluation of the quality of constructed loop(s). It is also
possible to use alternative rationales for evaluation based on
biological functions. We show here some examples of biological
functions that can include, exclude or guide the modeling
process such as hydrophobicity, accessibility of loop residues
to glycosylation or to binding of ions. (5) Side-chain modeling
is directly affected by template sequence identity, alignment
and backbone. Identical residues in two homolog proteins have
nearly identical rotamers. The SWISS-MODEL server (Bordoli
et al., 2009) and Modeller (Webb and Sali, 2014) are among
the most commonly used platforms for backbone/side-chain
homology modeling. Homology models are subjected to final
optimization and validation before conducting various kinds of
computational studies such as energetics (molecular mechanics),
protein-drug/protein-protein interactions (molecular docking
and protein networks), mutational analysis, and simulation in
physiological environment (molecular dynamics). (6) Model
optimization, also known as energy minimization, is application
of energy functions to compute a globalminimum that represents
the most native folding (Bordner, 2012). Minimization aims
to adjust the geometries of protein structures to the ‘‘force
field’’ parameters used in computational studies. This method
sometimes referred to as ‘‘relaxing the structure’’ is sufficient
to resolve atomic clashes in the model. However, the story is
not finished here. Several physical and structural errors should
be resolved. (7) Validation of the final model(s) checks if the
model complies with standard parameters of protein structure.
These parameters include: bond lengths, bond angles, torsions,
backbone outliers, rotamer outliers and all atomic contacts
(Chen et al., 2010). Evaluation procedure includes physics-based,
knowledge-based and experimental-based methods (Haddad
et al., 2016). The same rigorous rules of evaluation that are
applied in crystallography must also be applied in homology
modeling.
TARGETING NEUROBLASTOMA
Neuroblastomas are one of the most common and fatal solid
tumors in children below 2 years of age. Whereas the survival
rates of most types of cancer in children have improved in
the past few decades, neuroblastoma is still below 75% 5-year
survival (Siegel et al., 2016). Targeted therapy is a promising
approach for developing treatments of neuroblastoma. Matthay
et al. (2012) described three successful therapeutic targets for
neuroblastoma that are in practice today: (1) hNET targeted by
radiotherapy via 131I-metaiodobenzylguanidine (MIBG) (2) the
GD2 ganglioside targeted by monoclonal antibodies, and
(3) ALK targeted by kinase inhibitors. An extended list of targets
was previously compiled by Verissimo et al. (2011), including
those in clinical trials. The vast majority of FDA-approved
medicines, particularly those discovered by rational drug design
on molecular targets, work by perturbing the function of targets
to prevent or reverse symptoms/disease (Kinch et al., 2015).
It is important to distinguish the term targeted therapy, which
occasionally indicates perturbing the molecular target, from the
general concept of targeting which also includes drug delivery
by recognizing cancer cells. Hence, targeting also describes
therapeutics able to deliver and release cargo to the tumor
microenvironment by binding to targets on the cancer cell
surface (Shin et al., 2014). Such therapeutics (e.g., peptides and
antibodies) are characterized by their selectivity to targets. They
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can be developed either blindly via screening methods or by
molecular modeling. The ideal target should be ‘‘abundant and
accessible and should be expressed homogeneously, consistently
and exclusively on the surface of cancer cells’’ (Scott et al., 2012).
Homology modeling has been successfully used in structure-
based design of many therapeutics targeting different types of
diseases including cancer (Butler et al., 2010; Schlessinger et al.,
2011; DeVore and Scott, 2012). However, it is worth mentioning
two categories of excellent protein targets in neuroblastoma that
are beyond the scope of homology modeling: first, proteins
which have known crystal structures such as CD147, which is
associated with decreased neuroblastoma differentiation (Garcia
et al., 2009; Wright et al., 2014), and CD57, which has
also been implicated in aggression of neuroblastoma (Kakuda
et al., 2004; Schlitter et al., 2012). Second, those candidate
targets which lack any template structure. One of these
cases is a glycoprotein called CD133, and its expression is
associated with poor prognosis of neuroblastoma (Sartelet et al.,
2012).
In comparative modeling for development of drugs, the
lesson learned is that similar structures often exhibit similar
functions. This is problematic particularly when drugs target the
protein and its homologs simultaneously, resulting in various
side effects. The three targets hNET, ALK and TrkB are
good examples of cross interactions resulting in side effects.
While hNET neurotransmitter transport overlaps with other
monoamine transporters, the kinase inhibitors of ALK and
TrkB can target their homologs, respectively. Both homology
modeling and development of selective drugs should focus on the
low-conserved regions of targeted proteins.
hNET
The hNET regulates the uptake and recycle of norepinephrine
in the neurons. hNET is one of the highly expressed proteins
in neuroblastoma (∼90% of cases) and most commonly used
in MIBG-based diagnosis/therapy (Brodeur et al., 1993; Matthay
et al., 2012) and development of new therapeutics (Mortensen
and Kortagere, 2015). hNET protein has three isoforms. The
canonical isoform is 617 residues in length yet it is second
to the longest isoform which is 628 in length and differs in
the C-terminus. Previous homology models of hNET relied on
the crystal structure of prokaryotic leucine transporter (LeuT;
Yamashita et al., 2005) and drosophila dopamine transporter
(dDAT) crystal structures as templates (Penmatsa et al., 2013;
Wang et al., 2015; Table 1). Two recently published mutant
serotonin transporter (SERT) crystal structures (Coleman et al.,
2016) designated ts2 and ts3 can also aid in homology modeling
of hNET. The homologymodels constructed by Schlessinger et al.
(2011) and Koldsø et al. (2013) were based on LeuT template. In
light of newly published dDAT and SERT crystal structures, we
have recently addressed the developments regarding homology
modeling of hNET based on these new templates (Haddad et al.,
2016). Briefly, there are four major alignment gaps characterizing
the sequences of dDAT, hNET and SERT; including the
glycosylated extracellular loop 2 (EL2), extracellular loop 4
(EL4) and two intracellular loops (Figure 1A). Loop modeling
is mostly required at the EL2 loop; particularly residues
189–207. After construction of a number of loops, one should
exclude those with non-embedded leucines/valine residues due
to their hydrophobicity. At first glance, the accessibility to the
glycosylated residues can be an indicator of non-embedded
residues in the loop (i.e., asparagines). At least two glycosylated
forms of hNET are known with molecular weights of 80 kD and
54 kD corresponding to a core 46k D hNET protein (Melikian
et al., 1994). It is neither clear whether all three asparagines
are accessible for glycosylation nor if indeed there is a single
conformation of this loop. Mutant hNET (K189H) exhibits a
zinc binding site in the EL2 loop (Norregaard et al., 1998),
which might suggest direct proximity and accessibility between
K189 and nearest histidine H372. However, no information
is available on the proximity of H199 in the EL2 to these
residues. Similarly, several sodium and chloride ion binding
sites are reported in LeuT, dDAT and human SERT (hSERT;
Yamashita et al., 2005; Penmatsa et al., 2013; Wang et al., 2015;
Coleman et al., 2016). Ligands binding sites include the central
binding site (S1) and secondary binding site (S2) that overlaps
the extracellular loop (EL4; Figure 1A). Conserved residues
in binding sites described by Koldsø et al. (2015) have nearly
the same rotamers except for F317. Low-conserved residues in
binding sites described by Andersen et al. (2015) control the
selectiveness of hNET and side-chain conformations of these
residues can affect the quality of the model (shown in Figure 1A).
Asmentioned earlier, the side-chains of identical aligned residues
exhibit nearly identical rotamers. As many as 53 amino acid
residues in hNET that have identity with hSERT and not dDAT
can be used from the hSERT structure to complement the
rotamers and improve accuracy of structure (Haddad et al.,
2016). We recommend that the constructed homology model is
validated for selectivity by docking of previously known ligands
such as neurotransmitters and inhibitors.
ALK
ALK is a receptor tyrosine kinase originally discovered by
chromosomal rearrangement associated with anaplastic large
cell lymphoma. ALK was reported to be constitutively activated
by gene amplification in several neuroblastoma cell lines
(Osajima-Hakomori et al., 2005), while neuroblastoma-specific
mutations in ALK were suitable targets for development of
several inhibitor therapeutics (Barone et al., 2013). The three
classes of ALK mutations include a constitutively active gain-
of-function receptor (ligand-independent), kinase dead mutants,
and ligand-dependent mutants (Chand et al., 2013). Fusion
proteins involving the intracellular kinase domain of ALK
cause several types of cancer and has been targeted by kinase
inhibitors. In addition, several mutations in ALK kinase domain
result in drug resistance (Roskoski, 2013). The advantages
of homology modeling of the extracellular domains include
accessibility on cell surface and perhaps less cross interaction
than kinase inhibitors. ALK gene codes for a protein of
approximately 1620 residues (Table 1). The crystal structure
of the kinase domain shows the interactions of selective drugs
with mutant ALK (Sakamoto et al., 2011; Epstein et al., 2012;
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FIGURE 1 | Representations of the human norepinephrine transporter (hNET), anaplastic lymphoma kinase (ALK) and tropomyosin receptor kinase B
(TrkB) structures featuring the most divergent regions which require precise alignment and possibly loop modeling. Divergent loops are shown in
representative alignments with closest known homolog structures. (A) hNET. Two divergent extracellular loops and two intracellular loops are shown. A top view of
hNET is shown on the left. Low-conserved residues in binding sites as described by Andersen et al. (2015) are highlighted in colors: central binding site (S1),
secondary binding site (S2) and extracellular loop 4 (EL4). Red and blue circles highlight S1 and S2 sites, respectively. (B) ALK extracellular domains. Conserved
tryptophan in the MAM domains must be embedded in the center of structure (i.e., W288 and W501). Since the alignment of MAM2 (region of W501) was corrected
manually, further loop modeling of the region is required (particularly for P496 and P499). Highlighted conserved residues that are binding the calcium ion in the
Low-density lipoprotein receptor class A (LDLa) domain are important for alignment. (C) TrkB extracellular domains. Three major domains of the TrkB structure can
be used in analysis. The leucine rich repeat (LRR) and Ig-like C2 Type 2 regions can be constructed by homology modeling. Two shifts are shown, that might require
loop modeling. It is possible that divergent loops between Trk proteins might play role in the selectivity and cross-interactions with neurotrophins. The Ig-like C2 type
1 domain, directly connected to the transmembrane domain, has been illustrated by X-ray crystallography studies for the three Trks. Fitting of the three Trks showed
a divergent loop at TrkB 334–341 region; possibly playing role in the selectivity of these Trks to different neurotrophins.
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TABLE 1 | Templates for homology modeling of human norepinephrine transporter (hNET) and extracellular domains of anaplastic lymphoma kinase
(ALK) and tropomyosin receptor kinase B (TrkB).
Target (ID) Length Template (PDB IDs) Identity Coverage Main domains Reference
hNET (P23975) 617 LeuT (2A65) 150/541 (28%) 56−578 All Yamashita et al. (2005)
dDAT (4M48) 320/548 (58%) 56−601 All Penmatsa et al. (2013)
dDAT (4XPA) 322/547 (59%) 56−601 All Wang et al. (2015)
SERT-ts2 (5I6Z) 291/548 (53%) 51−595 All Coleman et al. (2016)
ALK (Q9UM73) 1620 PTPRM (2C9A and 2V5Y) 25/164 (15%)∗ 264−427 MAM1 Aricescu et al. (2006, 2007)
21/159 (13%)∗ 481−636 MAM2
MEP1B (4GWM) 19/164 (12%)∗ 264−427 MAM1 Arolas et al. (2012)
17/159 (11%)∗ 481−636 MAM2
LDLR (2KRI) 15/37 (41%) 437−473 LDLa Lee et al. (2010)
TrkB (Q16620) 822 TrkA (2IFG) 89/256 (35%) 32−281 Ig-like C2 Type2, LRR Wehrman et al. (2007)
∗Many identities were lost due to position-specific multiple alignment.
Huang et al., 2014). All known crystal models of ALK cover the
amino acid range 1058–1411 and unfortunately the extracellular
structure has not been well studied. The region spanning the
extracellular part of the receptor ∼266–636 comprises two
meprin/A5/mu domains also known as the MAM domains
(Figure 1). MAM1 spans 264–427 and MAM2 spans 478–636.
Approximately 16 N-linked glycosylated sites are recorded
sporadically in the extracellular region. Crystal structures of
the MAM domain of receptor protein tyrosine phosphatase
MU, also known as PTPRM (Aricescu et al., 2006, 2007), and
Meprin A beta, also known as MEP1B (Arolas et al., 2012)
can serve as multiple templates for the extracellular domain
of ALK. Although many sequence identities are lost due to
positional alignment (Table 1), the distinct MAM domains of
PTPRM andMEP1B are highly similar with∼1.35 Å root-mean-
square deviation (RMSD) of Cα atoms and ∼1.43 Å RMSD
for all atoms. Two loop regions in MAM1 domain require
loop modeling (Figure 1B). The former loop region contains
conserved tryptophan (W288) very well stacked in the center of
the domain. The equivalent tryptophan (W501) in MAM2 was
misaligned in the position-specific alignment and must be
corrected for proper modeling (Figure 1B). Similar to hNET,
glycosylated residues of the MAM domains can be used to check
the orientation of side chains as they should be facing solution.
A low-density lipoprotein receptor class A (LDLa) domain spans
the region 437–473 between the two MAM domains. The LDLR
structure (Lee et al., 2010) is the most related homolog (Table 1).
At least three conserved aspartic acid residues and one glutamic
acid coordinate a calcium ion in the LDLa domain (Figure 1B).
TrkB
The neurotrophic Trks, assisted by p75 neurotrophin receptor,
play an essential role in biology of neurons by mediating
neurotrophin-activated signaling. Neurotrophins include
nerve growth factor (NGF), brain-derived neurotrophic
factor (BDNF), neurotrophin-3 (NT-3), neurotrophin-4/5
(NT-4/5), neurotrophin-6 and neurotrophin-7 (Ultsch et al.,
1999). The expression of type 1 (TrkA) and type 2 (TrkB)
receptors is associated with favorable and unfavorable primary
neuroblastoma patient outcome, respectively (Thiele and
Reynolds, 2005). There are four protein isoforms of TrkA
reported in the Uniprot database (ID: P04629). The longest
is 796 residues in length. Crystal structures cover two large
segments of the extracellular; (Robertson et al., 2001; Wehrman
et al., 2007), and intracellular TrkA protein (Wang et al., 2012).
On the other hand, out of seven alternative isoforms, the
canonical isoform of TrkB is 822 residues in length (Table 1).
The crystal structures of TrkB cover the intracellular kinase
domain (Bertrand et al., 2012) and Ig-like C2 Type 1 domain
of the extracellular region (PDB IDs: 1WWB, 1HCF; Ultsch
et al., 1999; Banfield et al., 2001). The rest of extracellular
segment of TrkB (residues 32–281) can be reconstructed
by homology modeling of TrkA template which has ∼35%
identity (Table 1). The template allows for modeling of two
major extracellular domains of TrkB; namely, the leucine
rich repeat (LRR) spanning region 92–137, and the Ig-like
C2 Type 2 domain spanning the residues 197–281 (Figure 1C).
At least two alignment shifts in the LRR and Ig-like C2 type 2
domains require loop modeling. By superposing the three
known structures of Ig-like C2 type 1 domains of TrkA,
TrkB and TrkC (PDB IDs: 1WWA, 1WWB, and 1WWC,
respectively), a divergent loop spanning TrkB 334–341 region
is highlighted (Figure 1C). Along with this loop, several
divergent residues might also play role in the selectivity of
these Trks to different neurotrophins. However, further work
is required to identify the exact binding sites of different
neurotrophins (Ultsch et al., 1999). In fact, the network of
Trk-neurotrophin is more complex if we assume that either
Ig-like C2 Type 2 and LRR domains would be involved in
neurotrophins interactions. Intensive work in homology
modeling, molecular docking and molecular dynamics is
required to shed the light on this network. Similar to the
situation in hNET and ALK, inhibitors targeting several Trk
receptors at the same time result in targeting of several pathways
and lead to several drug side effects. Understanding the selectivity
of Trks receptors will play significant role in development of
therapeutics.
CONCLUSIONS AND PERSPECTIVES
Homology modeling is one of the first steps in developing
therapeutics for new targets. However, as we showed here the
first steps are often crucial and detrimental in constructing
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new homology structures, not to mention in developing new
drugs. Although the rules of ‘‘good modeling practice’’ are not
written yet, many lessons can be learned by evaluation of the
model and correcting/avoiding errors at early stages of modeling.
On the other hand, a bad quality template will not give a
good quality homology model. The quality and identity of the
template(s) are very important issues. Low-conserved regions in
the protein target often play a significant biological role. They
require more focus in homology modeling and in a design of new
therapeutics.
Several strategies for neuroblastoma therapy have been
advancing in parallel in the past few decades. Targeting the cell
surface molecules is a strategy that allows for distribution of
efforts. The distribution of efforts is defined by effective research
management where tasks are distributed among researchers
to produce more efficient therapeutics. Indeed, novel cancer
therapeutics comprise complexes of several agents that carry
out several functions. The selective targeting agent (e.g., peptide
or antibody) delivers the cargo (i.e., toxic agent) to the cancer
cell, which also requires a carrier (soluble/releasing agent) or
a membrane penetrating agent. In this perspective article, the
modeler has a more focused objective, which is to develop a
‘‘selective’’ targeting molecule. We hope that these strategies will
produce more adaptable, efficient and personalized therapeutics
in the future.
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